ARS Pharmaceuticals(纳斯达克代码:SPRY)近日宣布,公司将获得一笔400万美元的监管里程碑付款。此外,根据相关协议条款,该公司还有资格获得最高达8000万美元的销售里程碑款项。这一进展标志着公司在商业化进程中迈出重要一步,也为未来业绩增长提供了有力支撑。
ARS Pharmaceuticals(纳斯达克代码:SPRY)近日宣布,公司将获得一笔400万美元的监管里程碑付款。此外,根据相关协议条款,该公司还有资格获得最高达8000万美元的销售里程碑款项。这一进展标志着公司在商业化进程中迈出重要一步,也为未来业绩增长提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.